Literature DB >> 28344867

CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model.

Christina Gebauer1, Béatrice Pignolet2, Lidia Yshii3, Emilie Mauré1, Jan Bauer4, Roland Liblau1.   

Abstract

Paraneoplastic neurological disorders (PNDs) are rare human autoimmune diseases that mostly affect the central nervous system (CNS). They are triggered by an efficient immune response against a neural self-antigen that is ectopically expressed in neoplastic tumors. Due to this shared antigenic expression, the immune system reacts not only to tumor cells but also to neural cells resulting in neurological damage. Growing data point to a major role of cell-mediated immunity in PNDs associated to autoantibodies against intracellular proteins. However, its precise contribution in the pathogenesis remains unclear. In this context, our study aimed at investigating the impact of anti-tumor cellular immune responses in the development of PND. To this end, we developed an animal model mimicking PND. We used a tumor cell line expressing the hemagglutinin (HA) of influenza virus to induce an anti-tumor response in CamK-HA mice, which express HA in CNS neurons. To promote and track the T cell response against the HA antigen, naïve HA-specific CD8+ and/or CD4+ T cells, originating from TCR-transgenic animals, were transferred into these mice. We demonstrate that HA-expressing tumors, but not control tumors, induce in vivo activation, proliferation and differentiation of naïve HA-specific CD4+ and CD8+ T cells into effector cells. Moreover, both T cell subsets were needed to control tumor growth and induce CNS inflammation in CamK-HA mice. Thus, this new mouse model provides further insight into the cellular mechanisms whereby a potent anti-tumor immunity triggers a cancer-associated autoimmune disease, and may therefore help to develop new therapeutic strategies against PND.

Entities:  

Keywords:  Autoimmunity; T cells; central nervous system; paraneoplastic neurological disease; tumor immunity

Year:  2016        PMID: 28344867      PMCID: PMC5353919          DOI: 10.1080/2162402X.2016.1260212

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  42 in total

1.  Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice.

Authors:  P A Sillevis Smitt; G T Manley; J B Posner
Journal:  Neurology       Date:  1995-10       Impact factor: 9.910

2.  Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis.

Authors:  J Dalmau; H M Furneaux; R J Gralla; M G Kris; J B Posner
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

3.  Induction of cytotoxic T lymphocytes specific for paraneoplastic cerebellar degeneration-associated antigen in vivo by DNA immunization.

Authors:  K Sakai; T Shirakawa; Y Kitagawa; Y Li; G Hirose
Journal:  J Autoimmun       Date:  2001-12       Impact factor: 7.094

4.  Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis.

Authors:  W C Jean; J Dalmau; A Ho; J B Posner
Journal:  Neurology       Date:  1994-01       Impact factor: 9.910

5.  Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies.

Authors:  B Benyahia; R Liblau; H Merle-Béral; J M Tourani; J Dalmau; J Y Delattre
Journal:  Ann Neurol       Date:  1999-02       Impact factor: 10.422

6.  Effective and selective immune surveillance of the brain by MHC class I-restricted cytotoxic T lymphocytes.

Authors:  Julie Cabarrocas; Jan Bauer; Eliane Piaggio; Roland Liblau; Hans Lassmann
Journal:  Eur J Immunol       Date:  2003-05       Impact factor: 5.532

7.  Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.

Authors:  Setareh Shams'ili; Joost Grefkens; Bertie de Leeuw; Martin van den Bent; Herbert Hooijkaas; Bronno van der Holt; Charles Vecht; Peter Sillevis Smitt
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

8.  Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.

Authors:  Wendy K Roberts; Ilana J Deluca; Ashby Thomas; John Fak; Travis Williams; Noreen Buckley; Athanasios G Dousmanis; Jerome B Posner; Robert B Darnell
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

9.  Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss.

Authors:  M Tanaka; K Tanaka; O Onodera; S Tsuji
Journal:  Clin Neurol Neurosurg       Date:  1995-02       Impact factor: 1.876

10.  Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor.

Authors:  J Kirberg; A Baron; S Jakob; A Rolink; K Karjalainen; H von Boehmer
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity.

Authors:  Jenna L Collier; Sarah A Weiss; Kristen E Pauken; Debattama R Sen; Arlene H Sharpe
Journal:  Nat Immunol       Date:  2021-06-17       Impact factor: 31.250

2.  Management of Autoimmune Encephalitis: An Observational Monocentric Study of 38 Patients.

Authors:  Stefan Macher; Friedrich Zimprich; Desiree De Simoni; Romana Höftberger; Paulus S Rommer
Journal:  Front Immunol       Date:  2018-11-22       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.